Slide background

Slide background
Slide background
Slide background

Loading Events
January
2018
23
Five Points Lecture: Bobby Sebra, PhD

4:00 PM — 6:00 PM

“Understanding Complex Genetics of Human & Infectious Disease Leveraging Recent Advances in NGS and Molecular Technology”

See New York Genome Center’s lecture series, events and archives VIEW FULL CALENDAR

About

 

 

Associate Professor
Director of Technology Development
Icahn Institute and Department of Genetics and Genomic Sciences
Icahn School of Medicine at Mount Sinai

 

VP of Technology Development
Sema4, A Mount Sinai Venture

REGISTER

“Understanding Complex Genetics of Human & Infectious Disease Leveraging Recent Advances in Next-Generation Sequencing and Molecular Technology”

 

Whether surveying the human genome for complex structural variation or investigating various microbes related to infectious disease, advances in next-generation sequencing technology are rapidly enabling more robust references that include previously unachievable domains.  Dr. Sebra will discuss knowledge gained by comprehensive hybrid analysis of a human genome reference (NA12878) that integrates single molecule continuous long reads with genome maps alongside shorter reads for phasing variants.  This powerful combination of technologies facilitates a significantly improved assembly; resolving structure including gaps not addressed in previous human references using standard high throughput whole genome sequencing (WGS) data or either individual single-molecule platforms.  To read more about his findings, click this link.

 

Bobby Sebra, PhD, leads the Technology Development for Sema4 with technology adoption, and research and development to create high-throughput diagnostics and innovative IP. Dr. Sebra has vast experience in molecular, biochemical, and sequencing technology including surface bioconjugation techniques, lab-on-a-chip platforms, active biomaterials, single-molecule platforms, and the integration of bulk and single-cell sequencing technologies for basic science and clinically driven applications. He is a leading expert in sequencing platforms and a pioneer in new approaches for single molecule and single cell assay development. Dr. Sebra has published more than 50 papers in top tier journals, including Science, Cell, Nature, NEJM, and Cancer Discovery, and his work has led to multiple issued patents. To learn more about Dr. Sebra’s background, visit his lab page.

 

 

To learn more about Dr. Bobby Sebra’s research, visit Google Scholar – Robert Sebra, PhD

  • +
    FIVE POINTS
    Five Points lecture series bring leading scientists from around the world for an in-depth discussion of their work with students, researchers and clinicians from the New York Genome Center, its member institutions, and others in the medical/scientific community. While Five Points lectures are free and open to the general public, these lectures are most beneficial to scientists, clinicians and researchers who wish to accelerate their research through the use of DNA sequencing technology and bioinformatics. Five Points lectures often frame five or so key points, in a nod to the series’ name — followed by 15 minutes of Q&A, and 30 minutes of networking over hors d’oeuvres and cocktails. These afternoon events are held in the Center’s state-of-the-art ground-floor auditorium starting at 4 pm.

  • +
    EVENING TALKS
    The New York Genome Center’s Evening Talks events feature distinguished experts from around the world sharing genomic insights and research. They are intended to showcase and explain high science to the non-scientific community. Speakers present the latest research findings and explain its implication for helping improve clinical care for a wide array of serious diseases. The lecture is followed by a lively question-and-answer session and a post-event reception of hors d’oeuvres and cocktails. These popular free public events are held in the Center’s state-of-the-art ground-floor auditorium starting at 6:30 pm. The Evening Talks Series is sponsored by The New York Community Trust – Pyewacket Fund.